Acomplia moving ahead in Japan despite EU suspension
This article was originally published in Scrip
Executive Summary
The recent temporary suspension for Sanofi-Aventis's obesity drug Acomplia (rimonabant) in the EU has so far not affected development plans in Japan. The product has already completed a Phase IIb trial in this market and a Phase III programme is under way for both weight management and obesity-linked type 2 diabetes, with a submission scheduled for next year. These plans remain unchanged, Sanofi-Aventis's local subsidiary told Scrip. The EU suspension followed a review of the cannabinoid receptor blocker, which raised concerns over psychiatric safety (Scrip Online, October 24th, 2008).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.